Resumo

GARCIA, Anaí et al. Cost-effectiveness of vaccination for Haemophilus influenzae type b: A decision analysis in Cuba. Vaccimonitor [online]. 2002, vol.11, n.3, pp.1-5. ISSN 1025-028X.

The objective of the present study was to estimate the cost-effectiveness ratio of the therapeutic and prophylactic alternatives for treatment of meningitis caused by Haemophilus influenzae type b in less than one year old infants applying a mathematical model. A hypothetical setting with two alternatives was analyzed: to vaccinate or not to vaccinate. A 100% immunization coverage, as well as a 100% therapeutic coverage for sick persons were considered. The morbidity and lethality rates were taken from data for Cuba during 1998. The costs of the healing treatment and the immunization were calculated from a social perspective. An analysis of cost-effectiveness was modeled using the cost of each life saved as an indicator. For the vaccination alternative the use of conjugated vaccines was considered: Hibtiter (HBOC), Pedvax-Hib (PRP-OMP), Act-Hib (PRP-T) and, for the therapeutic treatment, third generation cephalosporins such as ceftaxidine and ceftriaxone. The unit cost of vaccination was 18.68 pesos for the HBOC and 14.01 pesos for the PRP-T and the PRP-OMP. The unit cost of treatment was 881.19 pesos. The cost-effectiveness ratio for the alternative not to vaccinate was 10.36 pesos for each life saved. For the vaccination alternative the cost-effectiveness ratio was: 0.19, 0.15, 0.20 pesos for each life saved respectively for the vaccines HBOC, PRP-OMP and PRP-T. Vaccination was a cost-effective alternative, the best results being achieved if the cost does not exceed $2.50 per dose with effectiveness values between 100% and 90%.

Palavras-chave : Cost-effectiveness; vaccine; meningitis; Haemophilus Influenzae.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )